Poxvirus-Based Vaccines for Cancer Immunotherapy: New Insights from Combined Cytokines/Co-Stimulatory Molecules Delivery and “Uncommon” Strains

Author(s): Valerio Izzi, Marcin Buler, Laura Masuelli, Maria G. Giganti, Andrea Modesti, Roberto Bei

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 2 , 2014

Become EABM
Become Reviewer
Call for Editor


Poxvirus-based vaccines have a long record of efficacy as both anti-tumour agents and vectors for gene therapy in different human tumour models. Interestingly, several studies of these vaccines have now entered the clinical evaluation phase for safety and effectiveness. A desirable outcome of antigen specific cancer immunotherapy is the disruption of host self-tolerance against endogenous tumour-associated antigens (TAAs). Nonetheless, recent studies have found reductions in vaccine efficacy due to host anti-vaccine immune reactions. Thus, newer approaches bringing together poxvirus-based vaccination and immunostimulation are being developed, and new poxvirus strains are being examined in tumour therapy studies.

Our review summarizes the current knowledge on the efficacy of poxvirus-based vaccination on human tumours, with a particular focus on approaches aimed at increasing innate and specific immune responses. Special attention will be devoted to the new poxvirus strains that are currently under consideration for tumour therapy; the current knowledge on clinical trials and outcomes will also be reviewed.

Keywords: Avipoxviruses, cancer vaccine, cytokines, immunostimulation, poxviruses, tumour-associated antigens.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 28 January, 2014
Page: [183 - 189]
Pages: 7
DOI: 10.2174/18715206113136660376
Price: $65

Article Metrics

PDF: 31